Programmed extracorporeal photochemotherapy in the complex treatment of systemic scleroderma

Abstract

The choice of non-drug methods for the treatment of systemic scleroderma is currently very limited. Several studies show that extracorporeal photochemotherapy can improve kidney and lung function and reduce skin fibrosis in patients with systemic scleroderma. We studied the dynamics of clinical and laboratory parameters in patients with systemic scleroderma with an assessment before and after 12 months against the background of complex treatment, which included programmed extracorporeal photochemotherapy. Indications for inclusion in the study was the ineffectiveness of standard therapy with glucocorticoids and cytostatics or the impossibility of their use, as well as signs of an unfavorable prognosis of the disease: diffuse form, high skin count (>14), rapid progression with a significant initial decrease in the glomerular filtration rate, forced vital capacity, high immunological activity (high titer of antinuclear factor and positivity for antibodies to Scl-70). When evaluating the results of complex treatment, a good clinical effect was observed in all patients: the induration of the skin decreased, the functionality of the lungs and kidneys increased. A significant decrease in the disease activity index was noted. These positive changes were the basis for a decrease in the daily dose of glucocorticoids. Significantly significant changes were observed in a decrease in the immunological activity of the disease: levels of C-reactive protein, erythrocyte sedimentation rate and immunoglobulin G, antinuclear factor titer and all types of circulating immune complexes. The results of our study confirm the data of other studies that demonstrated the positive effect of extracorporeal photochemotherapy as a component of the complex treatment of systemic scleroderma.

Keywords

systemic scleroderma / programmed extracorporeal photochemotherapy / basic therapy / immune response / total activity index / cellular immunity / humoral immunity

References

[1] Ананьева, Л. Лечение системной склеродермии с учетом Национальных рекомендаций и рекомендаций Европейской лиги по борьбе с ревматизмом (EULAR) // Фарм. – 2014. – Т. 283, № 10. – С. 79–86.

[2] Национальное руководство по ревматологии / Под ред. Е.Л. Насонова, В.А. Насоновой. – М.: ГЭОТАР-Медиа, 2008. – 720 с.

[3] Daoussis, D. Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions / D. Daoussis, S. Liossis // Mediterr. J. Rheum. – 2019. – Vol. 30, № 1 – P. 33–37.

[4] Du, A. Use of extrocorporeal photopheresis in scleroderma: a review / A. Du, M. Osman, R. Gniadecki // Dermatol. – 2020. – Vol. 236, – P. 105–110.

[5] Eugeniusz, J. Systemic sclerosis sine scleroderma / J. Eugeniusz, A. Kucharz A // Adv. Clin. Exp. Med. – 2017. – Vol. 26, № 2 – P. 875–880.

[6] Ipe, T. Critical updates in the 7th edition of the American society for apheresis guidelines / T. Ipe, H. Pham, L. Williams // J. Clin. Apher. – 2018. – Vol. 33, № 1. – P. 78–94.

[7] Kuzmina, Z. Extracorporeal photopheresis as a therapy for autoimmune diseases / Z. Kuzmina [et al.] // J. Clin. Apher. – 2015. – Vol. 30, № 4. – P. 224–237.

[8] Knobler, R. Guideline on the use extracorporeal photopheresis / R. Knobler [et al.] // JEADV. – 2014. – Vol. 28, № 1. – P. 17–18.

[9] Krasagakis, K. Management of severe scleroderma with long-term extracorporeal photopheresis / K. Krasagakis [et al.] // Dermatol. – 1998. – Vol. 196, № 3. – P. 309–315.

[10] Mayes, M. Scleroderma epidemiology / M. Mayes [et al.] // Rheum. Dis. Clin. North. Am. – 2003. – Vol. 29 – P. 239–254.

[11] Singh, D. Scleroderma: an insight into causes, pathogenesis and treatment strategies / D. Singh [et al.] // Pathophysiol. – 2019. – Vol. 26 – P. 103–114.

[12] Schwartz, J. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing Committee of the American society for apheresis: the seventh special issue / J. Schwartz [et al.] // J. Clin. Apher. – 2016. – Vol. 31, № 3. – P. 149–162.

[13] Van den Hoogen, F. Classification Criteria for Systemic Sclerosis: An ACR-EULAR Collaborative Initiative / F. van den Hoogen [et al.] // J. Artr. Rheum. – 2013. – Vol. 65, № 11. – P. 2737–2747.

[14] Voss, C. Extending the horizon for cell–based immunotherapy by understanding the mechanisms of action of photopheresis / C. Voss // Transfus. Med. Rev. – 2010. – Vol. 24, № 1. – P. 22–32.

[15] Ward, M. Extracorporeal Photopheresis: How, When, and Why / M. Ward // J. Clin. Apher. – 2011. – Vol. 26, № 5. – P. 276–285.

RIGHTS & PERMISSIONS

Manuilov A.S., Belskih A.N., Bardakov S.N., Apchel A.V., Tishko V.V., Zakharov M.V., Sokolov A.A., Ryabova T.S., Volkov K.Y., Vasylieva I.A.